Imago BioSciences, Inc. is a Delaware corporation that focuses on biotechnology and pharmaceutical research and development.

Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

COM:IMAGOBIO

Imago BioSciences, Inc.

Last Close

36.01

10/01 21:00

Volume Today

138.13K

Avg: -

market

industry

website

crunchbase

ipo date

competitor of

Metrics